Johnson & Johnson

Quantli Newsdesk

· a month ago

Johnson & Johnson received FDA de novo marketing authorization for its Ottava robotic surgical system, the first soft-tissue robot to integrate robotic arms into the operating table. The system is cleared for multiple general surgery procedures in the upper abdomen and will launch commercially with select U.S. customers, positioning J&J to compete in the robotic surgery market.

10-K

Quantli Newsdesk

· 4 months ago

Johnson & Johnson delivered $94.2 billion in sales (up 6.0%) with earnings before tax margin expanding to 34.6% from 18.8% in 2024, driven by Oncology strength and a $7.0 billion talc reserve reversal, while absorbing significant STELARA biosimilar erosion.